0.044
-0.001
(-2.22%)
May 21 - Close
ASX
data delayed by 20 mins -
Disclaimer
Currency in AUD
| Range | 0.04 - 0.05 |
| 52 week | 0.04 - 0.09 |
| Open | 0.05 |
| Vol / Avg. | 244,375.00/100.00 |
| Mkt cap | 16.92M |
| P/E | - |
| Div/yield | - |
| EPS | -0.01 |
| Shares | 384.53M |
| Beta | - |
| Inst. own | - |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -4279.22% | -1758.80% |
| Operating margin | -4618.15% | -1758.80% |
| EBITD margin | - | -1570.27% |
| Return on average assets | -58.07% | -95.88% |
| Return on average equity | -78.35% | -286.29% |
| Employees | 5 | - |
| Carbon Disclosure Rating | - | - |
Address
Unit 2, 120 Bluestone Circuit Seventeen Mile Rocks
BRISBANE, QLD 4073
Australia
+61-7-32950500 (Phone)
+61-7-32950599 (Fax)
BRISBANE, QLD 4073
Australia
+61-7-32950500 (Phone)
+61-7-32950599 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Invion Limited, formerly CBio Limited, is an Australia-based company. The Company is engaged in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the Company�s Cpn10 technology. The Company operates as a research and development company in the pharmaceutical industry. The Company has completed the Phase I studies with both intravenous and subcutaneous administration, and three intravenous dosing Phase II clinical trials in rheumatoid arthritis (RA), psoriasis and multiple sclerosis. In August 2012, the Company announced the merger with the United States-based Inverseon Inc. was completed to create Invion Limited.
Officers and directors
| Ralph Craven | Chairman of the Board | |
| Daina Vanags | Acting Chief Executive Officer, Chief Scientific Officer | |
| Greg Collier | Chief Executive Officer, Managing Director | |
| William J Garner MD | Chief Executive Officer, Managing Director | |
| Tom Coogan | Chief Financial Officer | |
| Mitchell Glass M.D. | Executive Vice President - Research & Development, Chief Medical Officer | |
| James A. Campbell Ph.D. | Executive Director | |
| Melanie Farris | Company Secretary | |
| Warren Brown | Non-Executive Director | |
| Brett Heading | Non-Executive Director |